BlueChip Wealth Advisors LLC Acquires New Stake in AbbVie Inc. $ABBV

BlueChip Wealth Advisors LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, Holdings Channel.com reports. The firm bought 2,311 shares of the company’s stock, valued at approximately $535,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Wealthstream Advisors Inc. increased its position in shares of AbbVie by 3.4% during the third quarter. Wealthstream Advisors Inc. now owns 2,107 shares of the company’s stock worth $488,000 after acquiring an additional 70 shares in the last quarter. Providence Capital Advisors LLC grew its stake in shares of AbbVie by 2.7% in the 3rd quarter. Providence Capital Advisors LLC now owns 17,917 shares of the company’s stock worth $4,148,000 after acquiring an additional 465 shares in the last quarter. Opinicus Capital Inc. raised its holdings in shares of AbbVie by 7.0% in the third quarter. Opinicus Capital Inc. now owns 10,952 shares of the company’s stock valued at $2,536,000 after purchasing an additional 714 shares during the last quarter. Wealthfront Advisers LLC lifted its position in shares of AbbVie by 9.2% during the third quarter. Wealthfront Advisers LLC now owns 175,400 shares of the company’s stock valued at $40,612,000 after purchasing an additional 14,845 shares in the last quarter. Finally, Navellier & Associates Inc. lifted its position in shares of AbbVie by 0.9% during the third quarter. Navellier & Associates Inc. now owns 31,210 shares of the company’s stock valued at $7,226,000 after purchasing an additional 278 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ABBV. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research note on Tuesday, November 4th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and increased their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Evercore cut their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. JPMorgan Chase & Co. raised their target price on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, Scotiabank began coverage on AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie Price Performance

NYSE:ABBV opened at $222.32 on Wednesday. The business has a fifty day simple moving average of $223.67 and a two-hundred day simple moving average of $220.29. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a market capitalization of $392.93 billion, a P/E ratio of 94.20, a P/E/G ratio of 0.78 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.